[Newsmp] While pharmaceutical stocks continued to struggle in August, most of the net purchases by investors were below KRW 10 billion.
Institutions and foreigners largely bought Celltrion, but individuals sold heavily, showing a different trend.
According to the Korea Exchange, institutional investors sold a net over KRW 10 billion of only two stocks, Celltrion and Samsung Biologics, among 46 pharmaceutical stocks in the KOSPI market in August.
Yuhan Corporation, Hami Pharmaceutical and GC Pharma recorded net sales of more than KRW 10 billion by institutional investors.
The institution’s net purchase of Celltrion was KRW 77.7 billion, the only one that exceeded KRW 20 billion, followed by Samsung Biologics with KRW 10 billion.
On the other hand, institutions sold a net KRW KRW 16.5 billion for Yuhan Corporation, KRW 13.3 billion for Hanmi Pharmaceutical, and KRW 12.2 billion for GC Pharma.
Foreign investors were also attached to Celltrion. During the same period, net purchases by foreigners for Celltrion reached KRW 98.2 billion.
Followed by Celltrion, they purchased a net KRW 15.4 billion for Yuhan Corporation, and KRW 15.3 billion for Hanmi Pharmaceutical, exceeding KRW 10 billion in net purchase for three stocks.
However, net sales for SK Bioscience and Samsung Biologics were over KRW 10 billion with KRW 14.2 billion and KRW 13.8 billion.
Individual investors have cleared up Celltrion. They sold a net KRW 174.6 billion in a month. Following Celltrion, net sales for Shinpoong Pharmaceutical were KRW 12.6 billion.
In the meantime, individual investors who sold a net of more than KRW 10 billion for Celltrion and Shinpoong Pharmaceutical purchased a net over KRW 10 billion for GC Pharma and SK Bioscience, but the volume did not exceed KRW 20 billion with KRW 18.2 billion and KRW 15.8 billion.
